ROR1 and breast carcinoma: Evidence suggests that these findings are also valid in vivo, as ROR1 knockdown significantly reduced the capacity of breast cancer cells intravenously injected into immunodeficient mice to invade the lung 24 to 72 h after injection [42], pointing to a role for ROR1 in extravasation and adhesion due to its control of the EMT phenotype.